

Tuesday – May, 2nd



For the Recovery of the High Vaccination Rates Project in Brazil (Auditorium – Centro Administrativo Vinicius Fonseca)

Open access to all participants

8:30 – 9:30	<p>Round table 1A – The challenge of Low Vaccination Coverage Situation in Brazil and Worldwide</p> <ul style="list-style-type: none"> • Brazil - Ethel Maciel, SVS / Brazilian MoH* • Americas – Jarbas Barbosa, PAHO* • WHO - Samir Sodha, IVB/WHO <p>Chair: Akira Homma, Fiocruz*</p>
9:30 – 10:00	Coffee break
10:00 – 11:00	<p>Round table 1B – How to overcome the low vaccination Coverage Challenges? Brazilian field experiences</p> <ul style="list-style-type: none"> • Creating connections with vulnerable groups – Oiapoque / Teatro Maiuhi, Elissandra Barros da Silva, Pet Indígena – Unifap* • Strategies to reconquest the high vaccination coverages in Paraíba State, Renata Nóbrega, Health Surveillance Unit from Paraíba* • For the Recovery of the High Vaccination Rates Project in Brazil through solidarity networks, Maria de Lourdes de Sousa Maia, PRCV Bio-Manguinhos*
11:00 – 11:30	<p>Round table 1C – Challenges and perspectives for SUS to strengthen vaccination in Brazil</p> <ul style="list-style-type: none"> • Primary health care agenda, Nesio Fernandes, Secretary of Primary Health Care, Ministry of Health* • Health surveillance agenda, Eder Gatti, Director, Department of Immunization and Preventable Diseases, Ministry of Health*



Easy ISI – Mini courses with high level information for beginners

Subscription needed at the event's website

8:30 – 11:00	<p>Easy ISI 01 Auditorium Rocha Lima Pavillion</p>	<p>Nanotechnology in Biopharmaceuticals and Vaccine development (Coordinators: Perla Villani, Aline Oliveira, Ana Paula Ano Bom and Renata Chagas)</p> <ul style="list-style-type: none"> - Kaique Alves Brayner Pereira, Fiocruz/Bio-Manguinhos* - Vinicius de Lima Gonçalves, Fiocruz/Bio-Manguinhos*
	<p>Easy ISI 02 Capacity Building Center - Centro Administrativo Vinicius Fonseca</p>	<p>Antimicrobial resistance (Coordinators: José Procópio Senna / Ivna Alana)</p> <ul style="list-style-type: none"> - One Health and multi-resistant bacteria, Ana Paula D'Alincourt Assef, Fiocruz/IOC* - Bacterial vaccines and antimicrobial resistance and antibacterial agents in clinical and pre-clinical development, José Procópio Moreno Senna, Fiocruz/Bio-Manguinhos*

Guided Tour Museu da Vida and Fiocruz Castle

Subscription needed at the event's website
(Meeting at the Foyer – Centro Administrativo Vinicius Fonseca)

9:30 – 11:00	Guided visit to Bio-Manguinhos' vaccine and biopharmaceuticals production site / Museu da Vida and Fiocruz Castle
--------------	---

Main Scientific and Technological Agenda
Tuesday – May, 2nd
(Auditorium / Foyer – Centro Administrativo Vinícius Fonseca)
Open access to all participants

11:30 13:00	<p>Science talks 1 – Poster session (exhibition + pitch) / Lunch box</p> <p>11:40 – 12:10 – Poster pitch - VACCINATION COVERAGE IN BRAZIL</p> <p>1.1 VAC-06 - Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate, Rita Soares Barbosa Cardona, USP</p> <p>1.2 ORT-18- Human papillomavirus vaccination coverage in Brazilian North Region, 2013-2022, Mateus de Paula Von Glehn, EpiSUS</p> <p>1.3 VAC-18 - Analysis of the possible factors associated with a low vaccination coverage among health Science undergraduates, Camila Costa dos Santos, UFF</p> <p>12:20 – 12:50 – Poster pitch - IMMUNE RESPONSE AND COVID-19</p> <p>1.4 VAC-05 - Comparative Evaluation of Antibodies Response against Spike RBD Epitopes of SARS-CoV-2 in Immunized, Maria Eduarda Santos Monteiro, Fiocruz/CDTS</p> <p>1.5 VAC-09- Observational study of immunogenicity, effectiveness and reactogenicity in 6 months to 17 years age group of vaccines against COVID-19, Camila Amormino Corsini, Fiocruz/Minas IRR</p> <p>1.6 IVD-06- New approaches in the detection of neutralizing antibodies using SARS-CoV-2 as a model, Caio Bidueira Denani, Fiocruz/Bio-Manguinhos</p>
13:00 14:00	<p><u>Opening session</u></p> <p>Coral da Fiocruz</p> <ul style="list-style-type: none"> ▪ Carlos Augusto Graboio Gadelha, Brazilian MoH* ▪ Mario Santos Moreira, Fiocruz* ▪ Maurício Zuma, Fiocruz/Bio-Manguinhos* <p>Chair: Akira Homma, Bio-Manguinhos*</p>
14:00 14:30	<p>Poster Oral Presentation 1 (VAC)</p> <ul style="list-style-type: none"> • VAC-01 - Humoral and cellular responses to SARS-CoV-2 variants after AstraZeneca/COVISHIELD vaccination in the primary protocol and follow-up, Artur Silva Vidal Capão, Fiocruz/IOC <p>Poster Oral Presentation 2 (VAC)</p> <ul style="list-style-type: none"> • VAC-02 - Immunogenicity and protection evaluation of a live attenuated chimeric vaccine for zika virus in mice model, José Henrique Rezende Linhares, Fiocruz/Bio-Manguinhos
14:30 15:20	<p>Science talks 2 – Poster session (exhibition + pitch) / Coffee break</p> <p>14:40 – 15:10 – Poster pitch - VACCINOLOGY</p> <p>2.1 VAC-03 - An alphavirus-derived replicon polyvalent RNA vaccine induces neutralizing antibodies in mice against omicron SARS-CoV-2 variant of concern, Vinicius Pinto Costa Rocha, SENAI CIMATEC</p> <p>2.2 VAC-08 - Integrating Next-Generation Phage Display and bioinformatics approaches for the screening of B-cell epitopes of different antigens using polyclonal sera, Alexsander de Moraes, USP - Faculdade de Medicina de Ribeirão Preto</p> <p>2.3 VAC-07 - Intranasal Vaccinal strategy targeting mucosal surface for methicillin-resistant Staphylococcus aureus (MRSA) decolonization, Juliana Georg da Silva, Fiocruz/Bio-Manguinhos</p>
15:20 16:20	<p><u>Panel I - Vaccines</u></p> <p>New technologies for accelerating vaccine development and new delivery methods</p> <ul style="list-style-type: none"> • Adjuvants – Charles Lutsch, Sanofi* • Vaccine development in 100 days - Ann-Muriel Steff, CEPI* <p>Chair: Sotiris Missailidis, Bio-Manguinhos*</p>
16h20 – 17h00	<p>Satellite Symposium 1 – Sanofi</p> <p>Vaccine hesitancy and the risk of polio re-emergence</p> <ul style="list-style-type: none"> • Causes of vaccine hesitancy, data from the study on low vaccine coverage and adverse effects, José Cassio* • Risk of Polio re-emergence in Brazil, Luiza Helena*

8:00 – 8h20

Morning warm up (Foyer – NAPA)



Innovation Hub

(Auditorium – Centro Administrativo Vinicius Fonseca)

Open access to all participants

8:30 – 9:20	<p>Round table IH1– Innovation strategy to meet public health needs in Brazil</p> <ul style="list-style-type: none"> ▪ Carlos Augusto Grabois Gadelha, SCTIE/MoH ▪ Igor Manhães Nazareth, Embrapii <p>Chair: Artur Couto, Fiocruz/Bio-Manguinhos</p>
9:20 – 10:10	<p>Round table IH2– Innovation strategy at Fiocruz to meet public health needs in Brazil</p> <ul style="list-style-type: none"> ▪ Presenting: Marco Krieger* ▪ Debators: Antonio Ferreira*, Carlos Morel*, Pedro Barbosa*, Camille Giaretta Sachetti* <p>Chair: Sotiris Missailidis, Fiocruz/Bio-Manguinhos*</p>
10:10 – 10:40	Coffee break
10:40 – 11:30	<p>Round table IH3– Biopharmaceutical technological development models to accelerate product supply in the market adopted by Bio-Manguinhos</p> <ul style="list-style-type: none"> • Articulation for the development of partnerships in biosimilars, Anna Erika* • Tech transfer, Antonio Barbosa* • Service-linked product development, Carla Lemos Gottgroy* • WHO vaccine development hub, Patricia Neves* <p>Chair: Hugo Defendi, Fiocruz/Bio-Manguinhos *</p>



Easy ISI – Mini courses with high level information for beginners

Subscription needed at the event's website

8:30 – 11:00	<p>Easy ISI 03 Virtual only</p>	<p>Bioinformatics applied to immunobiologicals (Coordinators: Mayla Abraham Costa / Alexandre Guterres da Silva / Monique Menegaci / Renato Astray)</p> <ul style="list-style-type: none"> - Mayla Abraham Costa, Fiocruz/Bio-Manguinhos* - Alexandre Guterres da Silva, Fiocruz/ Bio-Manguinhos *
	<p>Easy ISI 04 Capacity Building Center - Centro Administrativo Vinicius Fonseca</p>	<p>Industry 4.0 and its tools (Coordinators: Felipe Rodrigues / Fernando Serva / Luiz Lima)</p> <ul style="list-style-type: none"> - Introduction of the concepts, elements and tools proposed by Industry 4.0 for application in the biopharmaceutical industry, Fabricio Costa, Deloitte* - Successful cases in the biopharmaceutical industry (related to the era 4.0), Douglas Mariotoni, Nordika*

Guided Tour Fiocruz/Bio-Manguinhos

Subscription needed at the event's website
(Meeting at the Foyer – Centro Administrativo Vinicius Fonseca)

9:30 – 11:00	<p>Guided visit to Bio-Manguinhos' vaccine and biopharmaceuticals production site / Museu da Vida and Fiocruz Castle</p>
--------------	--

Main Scientific and Technological Agenda

Wednesday – May, 3rd

(Auditorium / Foyer – Centro Administrativo Vinícius Fonseca)

Open access to all participants

11:30 13:00	<p>Science talks 3 – Poster session (exhibition + pitch) / Lunch box</p> <p>11:40 – 12:10 – Poster pitch - FROM INFECTIOUS DISEASES TO CANCER – NEW THERAPEUTIC APPROACHES</p> <p>3.1 ORT-02 - Improvement CAR-T cell therapy with ultra-fast protocol and IL-15 membrane bound addition, Luiza de Macedo Abdo, INCa</p> <p>3.2 ORT-03 - Evaluation of a betulinic acid nanosystem for cancer therapy, Natália Pereira da Rocha, Fiocruz</p> <p>3.3 ORT-08 - Synthesis of polymeric nanoparticles of a high potency second generation isoniazid derivative aiming tuberculosis treatment via direct delivery to the lung, Frederico Silva Castelo Branco, Fiocruz/Farmanguinhos</p> <p>12:20 – 12:50 – Poster pitch - BIOPHARMACEUTICALS AND CANCER</p> <p>3.4 ORT-07 - Anti-her2 CAR-T cells evaluation in an ovarian tumor preclinical model, Emmanuel Arthur Albuquerque Aragao, INCa</p> <p>3.5 BIO-04 - Structural modeling and design of scFv fragments from the antineoplastic antibody Brontictuzumab for enhanced binding to Notch1 NRR region, Aline de Oliveira Albuquerque, Fiocruz Ceará</p> <p>3.6 BIO-08 - Regulation of the epigenetic machinery in pancreatic cancer, Ricardo Alberto Chiong Zevallos, USP</p>
13:00 14:00	<p>Panel II- Biopharmaceuticals & Biotechnology</p> <p>Biopharmaceuticals encoded by RNA</p> <ul style="list-style-type: none">• CART Cells to threat cardiac injuries using mRNA, Joel Rurik, University of Pennsylvania*• Next generation lipid nanoparticles technology for extrahepatic delivery of RNA molecules, Jayesh Kulkarn, NanoVation*• Revolutionizing Antibody Discovery with Single-Cell Analysis, James Crowe, Vanderbilt Vaccine Center <p>Chair: Patricia Neves, Bio-Manguinhos*</p>
14:00 14:30	<p>Poster Oral Presentation 3 (BIO)</p> <ul style="list-style-type: none">• BIO-01 - Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells, Najla Santos Pacheco de Campos, Universidade Federal do ABC <p>Poster Oral Presentation 4 (MAN)</p> <ul style="list-style-type: none">• MAN-01 - Project For the Recovery of High Vaccination Coverage: innovation in structuring actions to promote vaccination at the local level, Isabel Cristina Alencar De Azevedo, Fiocruz/Bio-Manguinhos
14:30 15:20	<p>Science talks 4 – Poster session (exhibition + pitch) / coffee break</p> <p>14:40 – 15:10 – Poster pitch - NEW THERAPY APPROACHES</p> <p>4.1 BIO-03 - Development and Characterization of Anti-VLA4 Monoclonal Antibody as a Potential Biopharmaceutical for the Treatment of Multiple Sclerosis, Vitória Fernandes de Castro, Fiocruz/Bio-Manguinhos</p> <p>4.2 VAC-10 - Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model, Raissa Lima Gonçalves Pereira, UFMG</p> <p>4.3 BIO-05 - CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy, Thiago Lazari Machado, Fiocruz/Bio-Manguinhos</p>
15:20 17:00	<p>Panel III – Management of Biotech Development and Production in the 4th Industrial Revolution</p> <ul style="list-style-type: none">• First steps on the journey to the future of the productive sector, Igor Calvet, ABDI*• 4th Industrial Revolution in Biotech industry, Marcio Freitas, Aché• Applications of 4.0 solutions in the pharmaceutical industry, Fabricio Costa, Deloitte*• 4.0 platform for the new Bio-Manguinhos plant, Fernando Serva Cavalcanti Leite, Bio-Manguinhos* <p>Chair: Luiz Alberto Lima, Bio-Manguinhos*</p>

Thursday – May, 4th

8:00 – 8h20

Morning warm up (Foyer – NAPA)



Innovation Hub

(Auditorium / Foyer – Centro Administrativo Vinicius Fonseca)

Open access to all participants

8:30
–
11:30

Hands on digital transformation
MIDAL



Easy ISI – Mini courses with high level information for beginners

Subscription needed at the event's website

8:30
–
11:00

Easy ISI 05
Auditorium
Rocha Lima
Pavillion

Quality by Design Applied to the Development of Products

(Coordinators: Renato Astray / Iralice / Anna Erika / Caio Veloso)

- Lecture: Present the concepts of QbD and expose the scope of QbD in the pharmaceutical industry - Diogo Dibo, Fiocruz/Farmanguinhos*
- Case Study: Application of QbD for analytical development of vaccines – Caroline Perez, Butantan*

Easy ISI 06
Bio-Manguinhos' training room – NAPA 1st floor

New methodologies and platforms for Diagnosis

(Coordinators: Antonio Gomes Pinto Ferreira / Elba Lemos / Patricia Alvarez)

- Remote diagnostics – PoC and Self-test - Wagner Tenório, Fiocruz/Bio-Manguinhos*
- Molecular diagnostics as a tool for diagnosis and epidemiological surveillance - Patricia Alvarez, Fiocruz/Bio-Manguinhos*
- Cancer diagnostics - technological challenges – Sheila Coelho, INCa*

Workshop on Biosimilars Updates

Evolution of the development, regulation and use of biosimilars: strengthening consensus for the Brazilian scenario

(only for invited guests)

Salão de Conferência Luiz Fernando Ferreira – COC/Fiocruz

8:30 8:40

WS open and presentation of dynamic of the day

8:40 9:10

Lecture WS 1

Are Clinical Trials Phase III necessary?

- Valderilio Feijo, Rheumatological Physician*
- Chair / rapporteur: Adriana Danowski, Fiocruz/Bio-Manguinhos*

9:10 9:40

Lecture WS 2

SB3 Trastuzumab – a biobetter?

- Mark Pregram, Stanford University
- Chair / rapporteur: Rosane Cuber, Fiocruz/Bio-Manguinhos*

9:40 10:00

Coffee break

10:00 11:30

Discussion and consensus

Chair: Hugo Defendi and Rosane Cuber, Bio-Manguinhos*

General rapporteurs: Anna Erika Vieira de Araujo* and Carla Lemos Gottgroy*, Fiocruz/Bio-Manguinhos

Main Scientific and Technological Agenda
Thursday – May, 4th
(Auditorium / Foyer – Centro Administrativo Vinícius Fonseca)
Open access to all participants

11:30 13:00	<p>Science talks 5 – Poster session (exhibition + pitch) / Lunch box</p> <p>11:40 – 12:10 – Poster pitch - TECHNOLOGICAL DEVELOPMENT AND INNOVATION TO CONTROL TO ENDEMIC INFECTIOUS DISEASES</p> <p>5.1 IVD-02 - Kit NAT PLUS HIV/HBV/HCV/Malária Bio-Manguinhos: Innovation and technological upgrade for NAT, Daniele Ramos Rocha, Fiocruz/Bio-Manguinhos</p> <p>5.2 ORT-04 - Evaluation of three antigens for the use in immunochromatographic rapid test for serological diagnosis of Human Visceral Leishmaniasis in Brazil, Allana Kelly Oliveira Dutra, Fiocruz/Bio-Manguinhos</p> <p>5.3 IVD-08- Evaluation of Influenza A and SARS-CoV2 detection using RT-PCR by paired saliva and nasopharyngeal secretions samples, Pedro Henrique Cardoso, Fiocruz/Bio-Manguinhos</p> <p>12:20 – 12:50 – Poster pitch - VIRUSES – FROM RAPID TEST TO MULTIPLEX ASSAY</p> <p>5.4 IVD-03 - A flow cytometry-based assay to measure neutralizing antibodies against SARS-CoV-2 virus, Veridiane Maria Pscheidt - UFCSPA</p> <p>5.5 ORT-09 - Usefulness of rapid molecular assay to detect hepatitis C virus, Vanessa Duarte da Costa, Fiocruz/IOC</p> <p>5.6 IVD-07 - Development of a multiplex RT-PCR molecular assay for Measles and Rubella viruses detection, Monica Barcellos Arruda, Fiocruz/Bio-Manguinhos</p>
13:00 14:00	<p>Panel IV - IVD</p> <p>Cancer diagnosis and core demands</p> <ul style="list-style-type: none"> • Diagnostics by sequencing and digital PCR. What can we expect? Ilana Zalcborg, INCa* • Real-time PCR and digital PCR applied to cancer diagnosis, John Young Lee, OPTOLANE Technologies Inc.* <p>Chair: Patricia Alvarez da Silva Baptista, Bio-Manguinhos*</p>
14:00 14:30	<p>Poster Oral Presentation 5 (IVD)</p> <ul style="list-style-type: none"> • IVD-01 - Detection of Plasmodium spp. in asymptomatic blood donors at Brazilian blood centers by the NAT PLUS HIV/HBV/HCV/MALARIA Bio-Manguinhos kit, Beatriz Vasconcello de Souza Barreto, Fiocruz/Bio-Manguinhos <p>Poster Oral Presentation 6 (ORT)</p> <ul style="list-style-type: none"> • ORT-01 - A high content image-based assay for detection and measurement of SARS-CoV-2 neutralizing antibodies, Vinicius Pinto Costa Rocha, SENAI CIMATEC
14:30 15:20	<p>Science talks 6 – Poster session (exhibition + pitch) / coffee break</p> <p>14:40 – 15:10 – Poster pitch - INFECTIOUS DISEASES</p> <p>6.1 ORT-05 - Evaluation of mutations in ABCB1 and ABCB11 genes by qPCR and their impact on the clinical evolution of hepatitis C, Leticia Bomfim Campos, Fiocruz/Instituto Oswaldo Cruz</p> <p>6.2 ORT-06 - Thiourea Derivatives with Antimycobacterial and Anti-Inflammatory Activity as an Adjuvant Treatment Strategy for Severe Pulmonary Tuberculosis, Sanderson Dias Calixto, UENF</p> <p>6.3 BIO-02 - Effect of lactoferrin as an immunomodulator and gene regulation of ferritin in different tissues of K18-hACE2 mice infected with SARS-CoV-2, Andrea Marques Vieira Da Silva - Fiocruz/Bio-Manguinhos</p>
15:20 16:30	<p>Grand Finale Round Table</p> <p>One Health and preparedness for the next pandemic</p> <ul style="list-style-type: none"> • A. Alonso Aguirre, Colorado State University* • Mariangela Simão, Instituto Todos Pela Saúde* • Ann-Muriel Steff, CEPI* • Meiruze Freitas, Anvisa* <p>Chair: Akira Homma, Bio-Manguinhos*</p>
16:30 – 17:00	<p>Poster Award Ceremony</p> <ul style="list-style-type: none"> ▪ Poster Award Independent Committee <p>Event close-up remarks</p> <p>Akira Homma, Bio-Manguinhos*</p>